

References

Books, Book Chapters, and Monographs

- Batts KP. Autoimmune and chronic cholestatic disorders of the liver. In: Odze RD, Goldblum JR, editors. *Surgical pathology of the GI tract, liver, biliary tract, and pancreas*. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1262–84.
- Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. *WHO classification of tumours of the digestive system*. 2nd ed. Lyon: IARC Press; 2014.
- Bioulac-Sage P, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationships with HCC. *Hepatology*. 2006;43:515–24.
- Boyer TD, Manns MP, Sanyal AJ, Zakim and Boyer's hepatology. *A textbook of liver disease*. 6th ed. Philadelphia, PA: Saunders Elsevier; 2012.
- Brunt EM, Tiniakos DG. Fatty liver disease. In: Odze RD, Goldblum JR, editors. *Surgical pathology of the GI tract, liver, biliary tract, and pancreas*. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1329–55.
- Burt A, Portman B, Ferrell L, editors. *MacSween's pathology of the liver*. 6th ed. Edinburgh: Churchill Livingstone, Elsevier; 2012.
- Demetris AJ, Crawford JM, Isse K, et al. Pathology of liver and hematopoietic stem cell transplantation. In: Odze RD, Goldblum JR, editors. *Surgical pathology of the GI tract, liver, biliary tract, and pancreas*. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1408–61.
- Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for liver allograft rejection: working recommendations for the histopathologic stagings and reporting of chronic rejection. An International Panel. *Hepatology*. 2000;31:792–9.
- Desmet VJ, Rosai J. Liver. In: Rosai J, editor. *Rosai and Ackerman's surgical pathology*. 10th ed. Elsevier Mosby: Edinburgh; 2011. p. 857–980.
- Ferrell LD. Benign and malignant tumors of the liver. In: Odze RD, Goldblum JR, editors. *Surgical pathology of the GI tract, liver, biliary tract, and pancreas*. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1539–72.
- Ferrell LD, Kakar S. *Liver pathology*. New York, NY: Demos Medical; 2011.
- Geller SA, Petrovic LM. *Biopsy interpretation of the liver*. 2nd ed. Philadelphia, PA: Wolters Kluwer Health; 2009. p. 90–92.
- Hübscher SG, Clouston AD. Transplantation pathology. In: Burt AD, Portman BC, Ferrell LD, editors. *MacSween's pathology of the liver*. 6th ed. Edinburgh: Elsevier Churchill Livingstone; 2012. p. 853–933.
- International Panel. Banff Schema for grading liver allograft rejection: an international consensus document. *Hepatology*. 1997;25:658–63.
- Kanel GC, Korula J. *Atlas of liver pathology*. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005.
- Le Bail B, Balabaud C, Bioulac-Sage P. Toxin- and drug-induced disorders of the liver. In: Odze RD, Goldblum JR, editors. *Surgical pathology of the GI tract, liver, biliary tract, and pancreas*. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1285–328.
- Lefkowitz JH. *Scheuer's liver biopsy interpretation*. 8th ed. Philadelphia, PA: Saunders, Elsevier; 2010.

- Ludwig J. Practical liver biopsy interpretation. Diagnostic algorithms. Chicago, IL: American Society of Clinical Pathologists; 1992.
- Moreira RK, Washington K. Liver neoplasms. In: Iacobuzio-Donahue CA, Montgomery E, editors. Gastrointestinal and liver pathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2012. p. 626–77.
- Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors—from molecular classification to personalized clinical care. *Gastroenterology*. 2013;144:888–902.
- Roy A, Crawford JM, Finegold MJ. Inherited metabolic and developmental disorders of the pediatric and adult liver. In: Odze RD, Goldblum JR, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1475–538.
- Strassburg CP, Manns MP. Liver biopsy (quality and use of gun). In: Boyer TD, Manns MP, Sanyal AJ, editors. Zakim and Boyer's hepatology. A textbook of liver disease. 6th ed. Philadelphia, PA: Saunders Elsevier; 2012. p. 173–83.
- Suriawinata AA, Thung SN. Liver pathology. An atlas and concise guide. New York, NY: Demos Medical; 2011.
- Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris N, editors. WHO classification of lymphoproliferative disorders. Lyons: IARC Press; 2008. p. 343–6.
- Theise ND, Saxena R. Algorithmic approach to diagnosis of liver diseases. In: Odze RD, Goldblum JR, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1143–69.
- Torbenson M. Biopsy interpretation of the liver. Philadelphia, PA: Wolters Kluwer Health; 2015.
- Xiao S-Y, Oshima K. Liver pathology. New York, NY: Demos Medical; 2015.
- Yeh MM, Crawford JM. Vascular disorders of the liver. In: Odze RD, Goldblum JR, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 1384–407.

Articles

- Bardou-Jacquet E, Philip J, Lorho R, et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. *Hepatology*. 2014;59:839–47.
- Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. *Am J Surg Pathol*. 1995;19(12):1409–17.
- Belghiti J, Cauchy F, Paradis V, Vilgrain V. Diagnosis and management of solid benign liver lesions. *Nat Rev Gastroenterol Hepatol*. 2014;11:737–49.
- Bioulac-Sage P, Sempoux C, Balabaud C. Immunohistochemical pitfalls in the diagnosis of focal nodular hyperplasia and inflammatory hepatocellular adenoma. *Clin Res Hepatol Gastroenterol*. 2014;38:245–9.
- Bravo AA, Sheth SG, Chopra S. Liver biopsy. *N Engl J Med*. 2001;344:495–500.
- Brunt EM, Gouw AS, Hubscher SG, et al. Pathology of the liver sinusoids. *Histopathology*. 2014; 64:907–20.
- Chute DJ, Sarti M, Atkins KA. Liver cytology. *Cancer Treat Res*. 2014;160:83–109.
- Costache MI, Iordache S, Karstensen JG, Săftoiu A, Vilmann P. Endoscopic ultrasound-guided fine needle aspiration: from the past to the future. *Endosc Ultrasound*. 2013;2:77–85.
- Denzer U, Arnoldy A, Kanzler S, et al. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. *J Clin Gastroenterol*. 2007;41:103–10.
- Dezsofi A, Knisely AS. Liver biopsy in children 2014: who, whom, what, when, where, why? *Clin Res Hepatol Gastroenterol*. 2014;38:395–8.
- Dhingra S, Fiel MI. Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics. *Arch Pathol Lab Med*. 2014;138:1090–7.
- Dohan A, Guerrache Y, Boudiaf M, et al. Transjugular liver biopsy: indications, technique and results. *Diagn Interv Imaging*. 2014;95:11–5.
- Frulio N, Chiche L, Bioulac-Sage P, Balabaud C. Hepatocellular adenomatosis: what should the term stand for! *Clin Res Hepatol Gastroenterol*. 2014;38:132–6.

- Gao PJ, Gao J, Li Z, et al. Hepatocellular carcinoma recurrence is an independent risk factor for HB recurrence after liver transplantation. *Hepatogastroenterology*. 2014;61:1523–8.
- Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. *J Hepatol*. 1995;22:696–9.
- Kerker N, Morotti RA, Madan RP, et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. *Pediatr Transplant*. 2010;14:504–11.
- Kim H, Lee K, Lee KW, et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. *Clin Transplant*. 2014;28:521–9.
- Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41:1313–21.
- Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy—indications, adequacy, quality of specimens, and complications—a systematic review. *J Hepatol*. 2007;47:284–94.
- Lo RC, Chan SC, Chan KL, et al. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. *J Clin Pathol*. 2013;66:392–8.
- Moreira RK, Salomao M, Verna EC, Brown Jr RS, Lefkowitz JH. The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C. *Am J Surg Pathol*. 2013;37:104–13.
- Navarro AP, Gomez D, Lamb CM, Brooks A, Cameron IC. Focal nodular hyperplasia: a review of current indications for and outcomes of hepatic resection. *HPB (Oxford)*. 2014;16:503–11.
- Ovchinsky N, Moreira RK, Lefkowitz JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. *Adv Anat Pathol*. 2012;19:250–62.
- Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. *Liver Transpl*. 2012;18:1147–53.
- Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. *Liver Transpl*. 2009;15:859–68.
- Pieri G, Theocharidou E, Burroughs AK. Liver in haematological disorders. *Best Pract Res Clin Gastroenterol*. 2013;27:513–30.
- Piselli P, Busnach G, Fratino L, et al. Immunosuppression and Cancer Study Group. De novo malignancies after organ transplantation: focus on viral infections. *Curr Mol Med*. 2013;13:1217–27.
- Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the study of liver diseases. Liver biopsy. *Hepatology*. 2009;49:1017–44.
- Rustagi T, Newton E, Kar P. Percutaneous liver biopsy. *Trop Gastroenterol*. 2010;31:199–212.
- Said A. Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. *World J Gastroenterol*. 2013;19:9146–55.
- Salomao M, Verna EC, Lefkowitz JH, Moreira RK. Histopathologic distinction between fibrosing cholestatic hepatitis C and biliary obstruction. *Am J Surg Pathol*. 2013;37:1837–44.
- Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma: epidemiological trends and risk factors. *Dig Dis*. 2009;27:80–92.
- Sempoux C, Balabaud C, Bioulac-Sage P. Pictures of focal nodular hyperplasia and hepatocellular adenomas. *World J Hepatol*. 2014;6:580–95.
- Sempoux C, Chang C, Gouw A, et al. Benign hepatocellular nodules: what have we learned using the patho-molecular classification. *Clin Res Hepatol Gastroenterol*. 2013;37:322–7.
- Shen S, Jiang L, Xiao GQ, et al. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. *World J Gastroenterol*. 2015;21:584–92.
- Shulman HM, Cardona DM, Greenson JK, et al. NIH consensus development on criteria for clinical trial in chronic graft-versus-host disease: II. The 2014 Pathology Working Group report. *Biol Blood Marrow Transpl*. 2015;21:589–603.
- Theise N. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. *Mod Pathol*. 2007;20:S3–14.
- Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. *Liver Transpl*. 2013;19:78–88.
- Yeh MM, Brunt EM. Pathological features of fatty liver disease. *Gastroenterology*. 2014;147:754–64.

Index

A

- Acute cellular rejection (ACR), 32, 33
 - holistic/Gestalt approach, 133
 - late onset, 130, 132
 - lobular based rejection, 130
 - pathologic hallmarks
 - bile duct inflammation/damage, 129, 131
 - portal inflammation, 129, 131
 - venous endohepatitis, 129, 132
 - plasma cell-rich rejection, 131, 133
- AIH. *See* Autoimmune hepatitis (AIH)
- Alcoholic hepatitis, 111
- Alcohol induced liver disease (ALD)
 - alcoholic hepatitis, 111
 - cirrhosis, 112
 - differential diagnosis, 112
 - Mallory-Denk bodies, 113
 - microscopic signs, 113
 - satellitosis, 113
 - steatohepatitis, 111, 113
 - steatosis, 111–113
- α_1 -antitrypsin (AAT) deficiency, 80, 81, 120–121
- Amyloidosis, 80, 81
- Angiosarcoma, 158, 159
- Anicteric hepatitis, 92
- Antibody mediated rejection (AMR), 135–136
- Antimitochondrial antibodies (AMA), 104
- Apoptotic hepatocyte, 23, 24
- ATP-dependent metal transporter, 118
- Autoimmune cholangitis, 106
- Autoimmune hepatitis (AIH), 32, 34, 60, 63
 - acute fulminant liver failure, 104
 - acute onset, 103
 - chronic, 103
 - corticosteroid and immunomodulator treatments, 104
 - differential diagnosis, 104
 - fulminant form with submassive necrosis, 103
 - grading and staging, 104
 - hypergammaglobulinemia, 101

- immune mediated chronic hepatitis,
 - women, 101
- interface hepatitis, 104
- no plasma cells, 104
- overlap syndrome, 95
- primary biliary cirrhosis overlap syndrome, 103
- principal microscopic features, 101–102

B

- Ballooned hepatocyte, 23, 24
- Batts-Ludwig system
 - for grading, 97, 98
 - for staging, 97, 99
- Bile duct adenomas, 154, 155
- Bile duct hamartomas, 35, 37, 153–154
- Bile ductule, 35, 36
- Biliary obstruction
 - cholestasis, histologic changes with, 111
 - common causes, 109
 - differential diagnosis, 110
 - drug reaction, 111
 - MRCP/ERCP, 111
 - pathology, 109–110
 - serologic data, 111
- Bridging fibrosis, 41, 42, 85, 86

C

- Centrilobular (perivenular) fibrosis, 85, 88
- Cholangiocarcinoma, 155, 156
- Cholestasis, injury patterns
 - bile lake, 56, 57
 - bile plugs, 55, 56
 - common causes, 55, 56
 - diagnostic evaluation, 58–60
 - dilated intercellular canaliculi, 55, 56
 - ductal, 58
 - intercellular bile canaliculi, 55, 56
 - periportal, 55, 57

Cholestatic hepatocellular rosettes, 55
 Chronic hepatitis, 29, 31
 Chronic hepatitis C, 32, 33, 95
 Chronic transplant rejection (CTR), 134, 135
 Cirrhosis
 ALD, 112
 chronic viral hepatitis, 94
 FNH, 147
 injury patterns, 85, 87
 liver transplantation, 123
 NAFLD, 114–115
 PBC, 105
 Congenital hepatic fibrosis (CHF), 153, 154
 Crohn disease, 106
 Cytomegalovirus (CMV) infection, 93, 94, 136–137

D

Donation after cardiac death (DCD), 127
 Drug induced liver injury (DILI)
 bilirubin, elevation of, 100
 bland cholestasis, 101
 centrolobular coagulation necrosis, 101
 classification, 99
 differential diagnosis, 100
 granulomas, 101
 histopathologic patterns, 99–100
 mild portal inflammatory infiltrates, 101
 pathologic and clinical findings, 99
 transaminase, elevation of, 100
 Ductal cholestasis, 58
 Ductal plate malformations (DPM), 153
 Ductopenia, 37, 38
 Ductopenic fibrosis, 107
 Ducts of Hering, 6, 7
 Ductular metaplasia, 37, 38
 Ductular proliferation, PSC, 107

E

EBV. *See* Epstein-Barr virus (EBV)
 Endoscopic retrograde cholangiopancreatography (ERCP), 106, 111
 Endothelial cells, 1, 3, 5
 Endotheliitis, 29, 30
 Epithelioid hemangioendotheliomas (EHEs), 157, 158
 Epstein-Barr virus (EBV)
 acute viral hepatitis, 33
 infection, 137
 Extensive liver cell death. *See* Massive necrosis

F

Feathery degeneration/choleate stasis, 23, 25
 Fibrin ring granulomas, 69, 70
 Fibrous obliterative cholangitis, 106

Fibrous septa, 41, 42
 Fine needle aspiration (FNA) biopsy, 14
 Florid duct lesion, 39, 40
 Focal lobular inflammation, 61, 64
 Focal nodular hyperplasia (FNH)
 differential diagnosis, 147
 fibrous tissue, thick muscular arteries, 147, 148
 glutamate synthetase immunohistochemical reaction, 146
 hypersignal, T2, 149
 irregular central fibrotic scar, 147, 148
 isosignal/faint hyposignal, T1, 149
 localized cirrhosis, 147
 radiologic findings, 149
 reticulin stain, 147

G

Graft preservation/reperfusion injury
 canalicular cholestasis, 126
 causes, 125
 cold ischemia, 127
 DCD, 127
 focal liver cell necrosis, 125
 hepatocytes, fatty change of, 126
 hepatocyte swelling, 126
 infection and sepsis, 127
 ischemic cholangiopathy, 125
 mild injury, 126
 persistent mild to moderate injury, 126
 persistent severe injury, 126
 Granuloma, 29, 30
 Granulomatous inflammation
 common causes, 66, 68
 diagnostic evaluation, 69, 70
 fibrin ring granulomas, 69, 70
 necrotizing granulomas, 68–69
 non-necrotizing granulomas, 68, 69

H

HCA. *See* Hepatocellular adenomas (HCA)
 HCC. *See* Hepatocellular carcinoma (HCC)
 Hemangiomas, 156, 157
 Hemochromatosis, 79
 Hemosiderosis, 23, 25
 Hepatic artery thrombosis (HAT), 127–128
 Hepatic fibrosis, injury patterns
 bridging fibrosis, 85, 86
 centrilobular (perivenular) fibrosis, 85, 88
 cirrhosis, 85, 87
 diagnostic evaluation, 85, 88–89
 periductal fibrosis, 84, 85
 perisinusoidal (pericellular) fibrosis, 85, 88
 porta hepatis, 84
 portal and periportal fibrosis, 84–86

- portal tracts, 84
 - replacement fibrosis, 85, 87
 - subcapsular fibrosis, 84
 - Hepatic iron index (HII), 118
 - Hepatic stellate cells, 1
 - Hepatocellular adenomas (HCA)
 - adenomatosis, 143
 - diagnostic and prognostic algorithms, 147
 - differential diagnosis, 146
 - in females, 141
 - histologic classification
 - β -catenin mutated HCA, 143
 - HNF1A inactivated HCA, 143, 144
 - non-mutated and non-inflammatory HCA, 144
 - telangiectatic/inflammatory, 144, 145
 - neoplastic hepatocytes, 141, 142
 - unpaired muscular arteries, 141, 143
 - Hepatocellular carcinoma (HCC)
 - architectural abnormalities, reticulin stain, 149, 151
 - architectural growth patterns
 - pseudoglandular/acinar, 149, 150
 - solid, 149, 150
 - trabecular, 149, 151
 - chronic hepatitis B, 149
 - glypican-3 immunohistochemistry, 146
 - HH, 118
 - marked nuclear atypia, 149, 152
 - metabolic syndrome, 149
 - nuclear atypia and nucleoli, 146
 - recurrence, liver transplantation, 139
 - special and immunohistochemical stains, 149, 152
 - survival and post-resection screening protocols, 153
 - Hepatocyte drop out/confluent necrosis, 26
 - Hepatocyte nuclear factor 1 alpha (HNF1A), 143, 144
 - Hepatocytes
 - bile formation, 6
 - cytoplasm of, 8
 - ducts of Hering, 6
 - intercellular biliary canaliculus, 4
 - lymphocytes, 4
 - minor nonspecific reactive changes, 49–51
 - one cell thick plates, 4, 5
 - space of Disse, 4
 - vascular (sinusoidal) and biliary pole, 4
 - Hepatopathology
 - biliary changes
 - bile duct, 35, 36
 - bile duct hamartoma, 35, 37
 - bile ductule, 35, 36
 - ductopenia, 37, 38
 - ductular metaplasia, 37, 38
 - ductular reaction, 37, 39
 - florid duct lesion, 39, 40
 - lymphocytic cholangitis, 39, 40
 - senescent bile ducts, 39, 41
 - fibrosis and architectural changes
 - bridging fibrosis, 41, 42
 - fibrous septa, 41, 42
 - nodular regenerative hyperplasia, 41, 43
 - pericellular/sinusoidal fibrosis, 43, 44
 - periductal fibrosis, 43, 44
 - hepatocellular changes
 - apoptotic hepatocyte, 23, 24
 - ballooned hepatocyte, 23, 24
 - feathery degeneration/choleate stasis, 23, 25
 - hemosiderosis, 23, 25
 - hepatocyte drop out/confluent necrosis, 26
 - Mallory-Denk bodies, 26, 27
 - steatohepatitis, 28, 29
 - steatosis, 26–28
 - inflammation
 - acute cellular rejection, 32, 33
 - autoimmune hepatitis, 32, 34
 - chronic hepatitis, 29, 31
 - chronic hepatitis C, 32, 33
 - endotheliitis, 29, 30
 - granuloma, 29, 30
 - interface hepatitis, 32, 34, 35
 - microabscess, 29, 31
 - sinusoidal lymphocytosis, 29, 32
 - Hereditary hemochromatosis (HH)
 - differential diagnosis, 117–118
 - ferri-ferrocyan, 116, 117
 - grading system, Mayo Clinic, 117
 - hemosiderin accumulation, 116
 - hepatocellular carcinoma, 118
 - HII, 118
 - iron homeostasis, 116
 - Perl's reaction, 116–117
 - semiquantitative grading, 118
 - trivalent ferri form, 116
 - Herpes simplex virus, 92
 - HH. *See* Hereditary hemochromatosis (HH)
 - Hodgkin lymphoma type PTLD, 137
 - Hypergammaglobulinemia, 101
- I**
- Immune mediated hypersensitivity DILI, 99
 - Immunoglobulin G4 associated sclerosing cholangitis, 108
 - Incisional wedge biopsy, 14
 - Infectious mononucleosis, 137
 - Injury patterns, 47
 - accumulations and depositions
 - AAT deficiency, 80, 81
 - amyloidosis, 80, 81

- Injury patterns (*continued*)
 diagnostic evaluation, 80, 82
 hemochromatosis, 79
 Wilson disease, 79–80
- cholestasis
 bile lake, 56, 57
 bile plugs, 55, 56
 common causes, 55, 56
 diagnostic evaluation, 58–60
 dilated intercellular canaliculi, 55, 56
 ductal, 58
 intercellular bile canaliculi, 55, 56
 periportal, 55, 57
- circulatory disturbances
 centrilobular sinusoids, 82, 83
 loss of centrilobular hepatocytes, 82, 83
 peliosis hepatis, 82
 terminal hepatic venule dilatation, 82, 83
- crucial caveats, 46
- fatty change (steatosis)
 diagnostic evaluation, 77, 78
 macrovesicular steatosis (*see*
 Macrovesicular steatosis)
 microvesicular steatosis, 76, 77
- fibrosis and cirrhosis
 bridging fibrosis, 85, 86
 centrilobular (perivenular) fibrosis, 85, 88
 cirrhosis, 85, 87
 diagnostic evaluation, 85, 88–89
 periductal fibrosis, 84, 85
 perisinusoidal (pericellular) fibrosis, 85, 88
 porta hepatis, 84
 portal and periportal fibrosis, 84–86
 portal tracts, 84
 replacement fibrosis, 85, 87
 subcapsular fibrosis, 84
- inflammation (hepatitis)
 acute hepatitis, 60, 61
 autoimmune hepatitis, 60, 63
 evaluation of, 60, 62
 focal lobular inflammation, 61, 64
 granulomatous inflammation (*see*
 Granulomatous inflammation)
 lobular hepatitis, 60, 63
 portal inflammation (*see* Portal
 inflammation)
- massive necrosis (*see* Massive necrosis)
- minor nonspecific reactive changes, 47, 48
 bile ducts, 49, 51, 52
 clinical indications, 54
 hepatocytes, 49–51
 infiltration of portal lymphocytes, 48–49
 inflammatory cells, 52, 53
 Kupffer cells, 52, 53
 laboratory findings, 55
 sinusoids, 54
- Interface hepatitis, 60. *See also* Portal
 inflammation
 AIH, 104
 chronic viral hepatitis, 94
 inflammation, 32, 34, 35
 portal inflammation, 62, 65
- Intraoperative frozen section biopsy, 21
- Iron homeostasis, 116
- Ischemic cholangitis, 109
- K**
- Kupffer cells, 1, 3–5
- L**
- Laparoscopic biopsy, 14
- Liver biopsy
 algorithmic approaches, 45–46
 function of, 11
 handling and processing
 embedding in paraffin and sectioning, 17
 fixation, 17
 gross examination and identification, 17
 immunohistochemical staining, 20–21
 intraoperative frozen section biopsy, 21
 microscopic examination, 21
 PAS stain with diastase pretreatment, 17,
 19
 PAS stain without diastase pretreatment,
 17, 19
 Perl's iron stain, 17, 18
 reticulin stain, 17, 20
 special stains, 17, 20
 trichrome stain, 17, 18
 indications, 11, 12
 position paper, 11–12
 reasons for, 11
 roles
 diagnostic value, 11–13
 prognostic value, 11, 13
 therapeutic value, 11, 13
 specimen
 adequacy of, 15
 other pathologic specimens, 15
 size and shape, 14–15
 techniques and modalities
 FNA biopsy, 14
 incisional wedge biopsy, 14
 laparoscopic biopsy, 14
 medical liver diseases, 13
 neoplastic liver diseases, 13
 percutaneous needle biopsy, 13–14
 transvenous biopsy, 14
 Liver cells proper. *See* Hepatocytes
 Liver transplantation pathology

ACR (*see* Acute cellular rejection (ACR))
 acute liver failure, 123
 AMR, 135–136
 biliary duct injuries, 128–129
 chronic obstructive cholangiopathy, 129
 cirrhosis, 123
 CTR, 134, 135
 drug related hepatitis, 139
 graft preservation/reperfusion injury
 canalicular cholestasis, 126
 causes, 125
 cold ischemia, 127
 DCD, 127
 focal liver cell necrosis, 125
 hepatocytes, fatty change of, 126
 hepatocyte swelling, 126
 infection and sepsis, 127
 ischemic cholangiopathy, 125
 mild injury, 126
 persistent mild to moderate injury, 126
 persistent severe injury, 126
 HAT, 127–128
 immunosuppressive therapy, complications
 CMV infection, 136–137
 immunohistochemistry with antibodies,
 138
 monoclonality, 138
 PTLD, 137
 malignancy transmission, 139
 malignant tumors, 123
 metabolic/genetic diseases, 123
 nodular regenerative hyperplasia, 139
 primary liver diseases, recurrence of
 hepatocellular carcinoma, 139
 hereditary genetic hepatic-based
 diseases, 138
 immune mediated liver diseases, 138
 steatosis, 138
 viral hepatitis B, 138
 viral hepatitis C, 138
 quality of graft, 124–125
 vascular injuries, 127
 Lobular hepatitis, 60, 63
 Lymphocytic cholangitis, 39, 40

M

Macrovesicular steatosis
 chronic viral hepatitis, 95
 common causes, 76
 steatofibrosis, 77, 78
 steatohepatitis, 77
 Magnetic resonance cholangiopancreatography
 (MRCP), 106, 111
 Mallory-Denk bodies, 26, 27, 113
 Massive necrosis, 92

causes of, 71
 centrilobular necrosis, 71–72
 coagulation necrosis, 72
 diagnostic evaluation, 74, 75
 drug induced necrosis, 72
 hepatic necrosis
 hydropic change, 74
 loss of nuclei and eosinophilic granularity,
 72, 73
 reticulin stain, 72, 74
 vacuolated hepatocytes, 74, 75
 herpes virus hepatitis, 72, 73
 midzonal necrosis, 71, 72
 multilobar confluent necrosis, 71
 periportal necrosis, 71, 72
 with and without inflammatory reaction, 72
 Masson's trichrome stains. *See* Trichrome stain
 Medical liver diseases, 13
 Microabscess, 29, 31
 Microvesicular steatosis, 28
 Monomorphic PTLD, 137
 Multilobar confluent necrosis, 71

N

NAFLD activity score (NAS), 115
 Necrotizing granulomas, 68–69
 Neoplastic liver diseases, 13
 Nodular regenerative hyperplasia, 41, 43
 Non-alcoholic fatty liver disease (NAFLD), 114–115
 Non-necrotizing granulomas, 68, 69
 Normal liver
 acinus division, 1, 4
 biliary system
 bile ductules, 6
 canaliculi, 6
 ducts of Hering, 6, 7
 hepatic artery branches, 4, 6–8
 immunohistochemical staining, 6, 7
 portal vein, 4, 6–8
 segmental bile duct, 6, 8
 septal bile duct, 4, 6
 septal portal tract, 6, 7
 sinusoids, 8
 centrilobular zone, 1, 3
 collagenous connective tissue, 1, 2
 with dilated sinusoids, 1, 3
 fibrous connective tissue, 1, 3
 functional division, 1
 liver cells, 1, 5
 lobules, 1, 2
 weight, 1
 Obliterative arteriopathy, 134

P

- PBC. *See* Primary biliary cirrhosis (PBC)
- Percutaneous needle biopsy, 13–14
- Pericellular/sinusoidal fibrosis, 43, 44
- Periductal fibrosis
 - architectural changes, 43, 44
 - hepatic fibrosis, injury patterns, 84, 85
 - PSC, 106, 107
- Periductal “onion skinning” fibrosis, 106, 107
- Periodic acid Schiff (PAS) stain, 17, 19
- Periportal PBC, 105
- Perisinusoidal (pericellular) fibrosis, 85, 88
- Perl’s iron stain, 17, 18
- Plasmacytic hyperplasia, 137
- Polymorphic PTLD, 137
- Portal and periportal fibrosis, 84–86
- Portal inflammation, 60
 - atypical lymphoid infiltrates, 66, 68
 - bile duct obstruction, 66, 67
 - diseases and conditions, 61, 64
 - eosinophils, 66, 67
 - interface hepatitis, 62, 65
 - lymphocytic infiltration, 62, 64
 - mixed lymphocytic and plasmacellular infiltration, 62, 65
- PBC, 61, 66
- PSC, 61
- Portal PBC, 105
- Post-transplant lymphoproliferative disorders (PTLD), 137
- Predictable dose related DILI, 99
- Primary biliary cirrhosis (PBC), 61, 66
 - autoimmune cholangitis, 106
 - chronic autoimmune cholangitis, 104
 - clinical and laboratory data, complex modeling of, 106
 - differential diagnosis, 106
 - elevated AMA, 104
 - florid duct lesion, 105
 - inflammation and epithelial damage, 104
 - pathognomonic histologic changes, 106
 - portal tract changes, 106
 - stages of, 105
- Primary sclerosing cholangitis (PSC), 61, 84, 85
 - autoimmune features, 109
 - characteristic features, 106
 - chronic nonspecific inflammation, 106, 107
 - Crohn disease, 106
 - differential diagnosis, 108
 - idiopathic vs. secondary sclerosing cholangitis, 109
 - IgG4 sclerosing cholangitis, 108, 109
 - overlap syndrome, 109
 - periductal “onion skinning” fibrosis, 106, 107

- small duct, 108
- stages, 107
- ulcerative colitis, 106

R

- Replacement fibrosis, 85, 87
- Reticulin stain
 - HCC, 149, 151
 - hepatic necrosis, 72, 74
 - liver biopsy, 17, 20
- Reversible and irreversible hepatocellular injury, 91

S

- Satellitosis, 113
- Senescent bile ducts, 39, 41
- Septal PBC, 105
- Sinusoidal lymphocytosis, 29, 32
- Space of Disse, 4
- Steatohepatitis
 - ALD, 111, 113
 - hepatocellular changes, 28, 29
 - macrovesicular steatosis, 77
 - NAFLD, 114
 - Wilson disease, 120
- Steatosis
 - ALD, 111–113
 - hepatocellular changes, 26–28
 - injury patterns
 - diagnostic evaluation, 77, 78
 - macrovesicular steatosis (*see* Macrovesicular steatosis)
 - microvesicular steatosis, 76, 77
 - NAFLD, 114
 - recurrence, liver transplantation, 138
- Subcapsular fibrosis, 84

T

- Terminal hepatic venule (THV), 1–4, 8
- Trichrome stain, 17, 18
- Tumors
 - angiosarcoma, 158, 159
 - benign tumors, 141
 - bile duct adenomas, 154, 155
 - bile duct hamartomas, 153–154
 - cholangiocarcinoma, 155, 156
 - EHEs, 157, 158
 - FNH (*see* Focal nodular hyperplasia (FNH))
 - HCA (*see* Hepatocellular adenomas (HCA))
 - HCC (*see* Hepatocellular carcinoma (HCC))
 - hemangiomas, 156, 157

- malignant tumors, 141
- standardized diagnostic approach, 141, 142

U

- Unpredictable idiosyncratic DILI, 99

V

- Viral hepatitis, acute
 - acute cholestatic hepatitis, 91
 - CMV infection, 93, 94
 - differential diagnosis, 92
 - Epstein-Barr virus, 93
 - hemorrhagic fever causing viruses, 93
 - herpes simplex virus, 92
 - lobular disarray, 91, 92
 - massive/submassive necrosis, 92
 - principal microscopic features, 91
 - resolving acute viral hepatitis, 92
 - reversible and irreversible hepatocellular injury, 91
- Viral hepatitis, chronic
 - autoimmune hepatitis overlap syndrome, 95
 - Batts-Ludwig system
 - for grading, 97, 98
 - for staging, 97, 99

- chronic hepatitis C, 95
- cirrhosis, 94
- differential diagnosis, 96
- fibrosing cholestatic hepatitis C and B, 95
- HBV surface and core antigen, 97
- portal chronic inflammation, 94
- principal microscopic features
 - apoptosis of hepatocytes, 94, 96
 - interface hepatitis, 94
 - Kupffer cell and mononuclear cell, 94, 96
 - lymphocyte infiltration, portal tract, 94, 95
 - macrovesicular steatosis, 95
 - portal-portal and portal-central bridging fibrosis, 95, 96
 - regenerating hepatocyte, 95

W

- Wilson disease, 79–80
 - ATP7B* gene mutation, 118
 - chronic hepatitis, 120
 - differential diagnosis, 119
 - fulminant hepatic necrosis, 120
 - pathology, 118–119
 - rhodanine, 120
 - steatohepatitis, 120